NCT04908059

Brief Summary

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 27, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 1, 2021

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 13, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 13, 2021

Completed
Last Updated

July 8, 2021

Status Verified

May 1, 2021

Enrollment Period

6 months

First QC Date

May 26, 2021

Last Update Submit

July 7, 2021

Conditions

Anaplastic Lymphoma

Keywords

Anaplastic lymphomaLeukemic phase

Outcome Measures

Primary Outcomes (1)

  • A retrospective study of the diagnostic description of the leukemic phases of anaplastic lymphoma in real life

    Files analysed retrospectively from January 01, 2020 to December 31, 2020 will be examined]

Eligibility Criteria

Age9 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients presenting a leukemic phase of anaplastic lymphoma

You may qualify if:

  • Patients presenting a leukemic phase of anaplastic lymphoma

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hematology Laboratory - Strasbourg University Hospitals

Strasbourg, 67091, France

RECRUITING

Study Officials

  • Laurent MAUVIEUX, MD, PhD

    Hematology Laboratory - Strasbourg University Hospitals

    STUDY DIRECTOR

Central Study Contacts

Laurent MAUVIEUX, MD, PhD

CONTACT

33 3 88 12 75 27laurent.mauvieux@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90said.chayer@chru-strasbourg.fr

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2021

First Posted

June 1, 2021

Study Start

January 27, 2021

Primary Completion

July 13, 2021

Study Completion

July 13, 2021

Last Updated

July 8, 2021

Record last verified: 2021-05

Locations

FR(1)